Clinical Stevens–Johnson syndrome and rufinamide: A clinical case

Chambel, Marta; Mascarenhas, Maria Isabel; Regala, Joana; Gouveia, Catarina; Prates, Sara

doi:10.1016/j.aller.2011.12.004

Cited by 9 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rash associated with RFN is usually mild, and only anecdotic cases have been reported with drug rash with eosinophilia and systemic symptoms (DRESS) syndrome 36 and Stevens-Johnson Syndrome (SJS) 37 associated to RFN treatment. Aromatic anticonvulsants are especially linked to anticonvulsant hypersensitivity syndrome (AHS), a potentially life-threatening condition, and there is a high degree of cross-reactivity among all these agents.…”

Section: Treatment-related Adverse Eventsmentioning

confidence: 99%

<p>Adjunctive Rufinamide in Children with Lennox-Gastaut Syndrome: A Literature Review</p>

Balagura¹,

Riva²,

Marchese³

et al. 2020

NDT

View full text Add to dashboard Cite

Lennox-Gastaut syndrome (LGS) is a severe, childhood-onset, developmental epileptic encephalopathy, with different etiologies and co-morbidities. Seizure treatment in LGS represents a major challenge; new antiepileptic drugs (AEDs) are developed to especially address seizures resulting in high morbidity and mortality, such as drop seizures. Rufinamide (RFN) is one of the latest AEDs licensed for patients with LGS. Its mechanism of action involves sodium channels in a way that is unrelated to other AEDs. Here we discuss the use of adjunctive RFN in children and adolescents with LGS and its efficacy and safety profile, based on a systematic literature review. RFN shows a very favorable profile in terms of adverse events and drug-interactions in children. It is particularly effective on tonic-atonic seizures and spasms, impacting on the quality of life of the patients. Further studies are needed to clarify the interaction profile with the newest AEDs for LGS and to assess correlations between the etiology of LGS and drug response to individualize treatment and maximize efficacy.

show abstract

Section: Treatment-related Adverse Eventsmentioning

confidence: 99%

<p>Adjunctive Rufinamide in Children with Lennox-Gastaut Syndrome: A Literature Review</p>

Balagura¹,

Riva²,

Marchese³

et al. 2020

NDT

View full text Add to dashboard Cite

show abstract

“…Likewise, Biton et al reported two cases of lymphopenia (one patient with low lymphocyte count and one patient with low lymphocyte concentration) and one case of neutropenia [62]. SAEs reported in case studies include drug-reaction with eosinophilia and systemic symptoms (DRESS) [71], Stevens-Johnson syndrome [72], two cases of suicidal ideation in the setting of bipolar disorder [73], severe constipation [74], and agranulocytosis [75]. RFM does have the potential to shorten QT interval and is contraindicated in patients with Familial Short QT syndrome [76].…”

Section: Rufinamidementioning

confidence: 99%

The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs

LaPenna

Tormoehlen

2017

J. Med. Toxicol.

View full text Add to dashboard Cite

Epilepsy is a neurologic disorder affecting approximately 50 million people worldwide, or about 0.7% of the population [1]. Thus, the use of anticonvulsant drugs in the treatment of epilepsy is common and widespread. There are three generations of anticonvulsant drugs, categorized by the year in which they were developed and released. The aim of this review is to discuss the pharmacokinetics, drug-drug interactions, and adverse events of the third generation of anticonvulsant drugs. Where available, overdose data will be included. The pharmacokinetic properties of third-generation anticonvulsant drugs include relatively fewer drug-drug interactions, as well as several unique and life-threatening adverse events. Overdose data are limited, so thorough review of adverse events and knowledge of drug mechanism will guide expectant management of future overdose cases. Reporting of these cases as they occur will be necessary to further clarify toxicity of these drugs.

show abstract

“…All cases were quickly reversible with drug discontinuation. However, more severe reactions to include Stevens–Johnson syndrome have been reported with rufinamide use [Chambel et al . 2012].…”

Section: Safety and Tolerabilitymentioning

confidence: 99%

Efficacy and safety of rufinamide in pediatric epilepsy

Hsieh

Thiele

2013

Ther Adv Neurol Disord

View full text Add to dashboard Cite

Rufinamide is a novel anticonvulsant medication approved by the US Food and Drug Administration (FDA) in 2008 for the treatment of seizures associated with Lennox-Gastaut syndrome in patients 4 years of age and older, based upon clinical trials demonstrating clinical efficacy and tolerability. Rufinamide is especially effective for tonic-atonic seizures in LennoxGastaut syndrome, but is subsequently proving to be safe and effective in clinical practice for a broad patient population with refractory epilepsy. Although further research and clinical experience is needed, rufinamide holds the promise to positively impact the care of children with epilepsy. In this review, we review the use of rufinamide in pediatric epilepsy, with a focus on efficacy and safety.

show abstract

Clinical Stevens–Johnson syndrome and rufinamide: A clinical case

Cited by 9 publications

References 8 publications

<p>Adjunctive Rufinamide in Children with Lennox-Gastaut Syndrome: A Literature Review</p>

<p>Adjunctive Rufinamide in Children with Lennox-Gastaut Syndrome: A Literature Review</p>

The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs

Efficacy and safety of rufinamide in pediatric epilepsy

Contact Info

Product

Resources

About